Literature DB >> 10837101

Serotonin and amino acids: partners in delirium pathophysiology?

R C van der Mast1, D Fekkes.   

Abstract

Delirium may be the result of dysfunction of multiple interacting neurotransmitter systems. Changes in the levels of various amino acids being precursors of cerebral neurotransmitters may affect their function and, thus, contribute to the development of delirium. Serotonin is one of the neurotransmitters that may play an important role in medical and surgical delirium. Normal serotonin synthesis and release in the human brain is, among others, dependent on the availability of its precursor tryptophan (Trp) from blood. The essential amino acid Trp competes with the other large neutral amino acids (LNAA) tyrosine, phenylalanine, valine, leucine, and isoleucine for transport across the blood-brain barrier. This competition determines its uptake into the brain, represented by the ratio of the plasma level of Trp to the sum of the other LNAA. The plasma ratio of Trp/LNAA, plasma level of Trp, and serotonin in plasma and platelets have been used as indirect peripheral measures for central serotonergic functioning. Both increased and decreased serotonergic activity have been associated with delirium. Serotonin agonists can induce psychosis, both elevated Trp availability and increased cerebral serotonin have been associated with hepatic encephalopathy, and excess serotonergic brain activity has been related to the development of the serotonin syndrome of which delirium is a main symptom. On the other hand, alcohol withdrawal delirium, delirium in levodopa-treated Parkinson patients, and postoperative delirium have been related to reduce cerebral Trp availability from plasma suggesting diminished serotonergic function. Rick factors for delirium such as severe illness, surgery, and trauma can induce immune activation and a physical stress response comprising increased activity of the limbic-hypothalamic-pituitary-adrenocortical axis, the occurrence of a low T3 syndrome, and, possibly, changes in the permeability of the blood-brain barrier. There are indications that these changes have their effect on plasma amino acid concentrations, e.g., Trp, and multiple cerebral neurotransmitters, including serotonin. This stress response may be different depending on the stage of illness being acute or chronic. It will require further study to determine the complex influence of the stress response and immune activation on plasma amino acids, neurotransmitter function and the development of delirium, especially in the more vulnerable older patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837101     DOI: 10.153/SCNP00500125

Source DB:  PubMed          Journal:  Semin Clin Neuropsychiatry        ISSN: 1084-3612


  17 in total

Review 1.  Delirium: an important (but often unrecognized) clinical syndrome.

Authors:  Terry Rabinowitz
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Duration of Agitation, Fluctuations of Consciousness, and Associations with Outcome in Patients with Subarachnoid Hemorrhage.

Authors:  Michael E Reznik; Ali Mahta; J Michael Schmidt; Hans-Peter Frey; Soojin Park; David J Roh; Sachin Agarwal; Jan Claassen
Journal:  Neurocrit Care       Date:  2018-08       Impact factor: 3.210

Review 3.  The role of tryptophan metabolism in postpartum depression.

Authors:  Kai-Ming Duan; Jia-Hui Ma; Sai-Ying Wang; ZhengDong Huang; YingYong Zhou; HeYa Yu
Journal:  Metab Brain Dis       Date:  2018-01-06       Impact factor: 3.584

4.  Tryptophan supplementation and postoperative delirium--a randomized controlled trial.

Authors:  Thomas N Robinson; Christina L Dunn; Jill C Adams; Carrie L Hawkins; Zung V Tran; Christopher D Raeburn; Marc Moss
Journal:  J Am Geriatr Soc       Date:  2014-08-12       Impact factor: 5.562

5.  The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness*.

Authors:  Jessica R Adams Wilson; Alessandro Morandi; Timothy D Girard; Jennifer L Thompson; Chad S Boomershine; Ayumi K Shintani; E Wesley Ely; Pratik P Pandharipande
Journal:  Crit Care Med       Date:  2012-03       Impact factor: 7.598

Review 6.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

8.  The SLC6A14 gene shows evidence of association with obesity.

Authors:  Elina Suviolahti; Laura J Oksanen; Miina Ohman; Rita M Cantor; Martin Ridderstrale; Tiinamaija Tuomi; Jaakko Kaprio; Aila Rissanen; Pertti Mustajoki; Pekka Jousilahti; Erkki Vartiainen; Kaisa Silander; Riika Kilpikari; Veikko Salomaa; Leif Groop; Kimmo Kontula; Leena Peltonen; Päivi Pajukanta
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 9.  Pharmacological management of delirium in hospitalized adults--a systematic evidence review.

Authors:  Noll Campbell; Malaz A Boustani; Amir Ayub; George C Fox; Stephanie L Munger; Carol Ott; Oscar Guzman; Mark Farber; Adetayo Ademuyiwa; Ranjeet Singh
Journal:  J Gen Intern Med       Date:  2009-05-08       Impact factor: 5.128

10.  Quetiapine Sustained Release in Treatment of Delirium Induced by Cerebral Metastasis.

Authors:  Antonino Messina; Anna Maria Fogliani
Journal:  Case Rep Oncol       Date:  2010-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.